Navigation Links
Coalition to Save Pure Files Proxy Documents With SEC, Urges Pure's Board to Set an Annual Meeting Date

NEW YORK, Dec. 23, 2011 /PRNewswire/ -- The Coalition to Save Pure, a group of stockholders and director nominees that has nominated a slate of six individuals to replace the current board of directors of Pure Bioscience, Inc. (NASDAQ: PURE), today filed its preliminary proxy statement with the Securities and Exchange Commission.

Pure owns the rights to silver dihydrogen citrate (SDC), an antibacterial, antiviral and antifungal technology.

In the filing, the Coalition outlined its reasons for seeking to replace the current board. "We believe that SDC holds substantial promise and that Pure has simply had the wrong people at the helm.  They have had more than enough opportunity to prove themselves, but have saddled the Company with operating losses and inflicted substantially diminished share value upon stockholders," the Coalition's filing stated.

The Coalition has also called upon Pure's Board of Directors to set a timely date for the Company's next annual meeting:

"It's time to give Pure's stockholders the choice between current management and new leadership.  January 19 marks one year since Pure's last annual meeting.  We urge Pure's board to schedule the next annual meeting without delay, so that stockholders can express their will and choose who they want to lead their company."

Additional Information

The Coalition to Save Pure consists of Jeffrey P. Bash, Theodore J. Coburn, C. James Jensen, Dr. Martin Kassir, Thomas J. Reynolds, Ph.D, John P. Rochon and Richmont Corporation, a Delaware corporation based in Plano, Texas, engaged in private investment and business management services. Richmont and each of Messrs. Bash, Coburn, Jensen, Kassir, Reynolds and Rochon (the "Participants") are or may be deemed to be "participants" under the rules of the Securities and Exchange Commission ("SEC") in the solicitation of proxies for the election of their slate of nominees to Pure Bioscience's board of directors. In connection with their intended proxy solicitation, the Participants have filed a preliminary proxy statement with the SEC and intend to file a definitive proxy statement with the SEC to solicit stockholders of Pure Bioscience. The Participants advise stockholders of Pure Bioscience to read their definitive proxy statement when it becomes available, because it will contain important information. That proxy statement, when filed, and any other relevant documents, are or will be available without charge on the SEC's website at In addition, the Participants in the solicitation will provide copies of the proxy statement and their other soliciting materials without charge upon request. Requests for copies should be directed to the Participants' proxy solicitor, MacKenzie Partners, Inc., toll-free at (800) 322-2885 or collect at (212) 929-5500 or via email at Information regarding the Participants, including their direct or indirect interests in the solicitation, by security holdings or otherwise, is contained in their preliminary proxy statement on Schedule 14A filed with the SEC on December 23, 2011, which is available without charge on the SEC's website at  

SOURCE The Coalition to Save Pure
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Coalition Applauds Introduction of Life Sciences Jobs and Investment Act
2. The Coalition to Prevent Deep-Vein Thrombosis (DVT) RV Tour Takes to the Road to Educate the Nation About the Importance of DVT Risk Assessment
3. Coalition for the Advancement of Medical Research Releases New White Paper, Catalyst for Cures: Embryonic Stem Cell Research
4. Matthew B. Wiener, CEO of Pharmatech, Inc., Is Awarded the Cancer Leadership Award From the Colorado Cancer Coalition
5. Vermillion and Stanford Scientists Receive Best Research Award From the PAD Coalition
6. National Ovarian Cancer Coalition and PureOlogy to Host First Annual NOCC and PureOlogys Walk to Break the Silence on Ovarian Cancer
7. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
8. China Cord Blood Corporation Files Its Annual Report on Form 20-F
9. Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination
10. Shire Files Lawsuits Against Watson and Roxane for Infringement of VYVANSE(R) (lisdexamfetamine dimesylate) Patents
11. Cephalon Files Definitive Consent Revocation Statement, Commences Mailing to Shareholders
Post Your Comments:
(Date:11/27/2015)... /PRNewswire/--  Mallinckrodt plc (NYSE: MNK ), a ... closed the sale of its global contrast media and ... in a transaction valued at approximately $270 million. The ... total of approximately 1,000 employees spread across the globe, ... area. This entire workforce and the manufacturing ...
(Date:11/27/2015)... PA (PRWEB) , ... November 27, 2015 , ... ... Technical Program that includes over 2,000 technical presentations offered in symposia, oral ... chemistry and applied spectroscopy, covers a wide range of applications such as, but ...
(Date:11/27/2015)... India , November 27, 2015 /PRNewswire/ ... --> Growing popularity of companion diagnostics ... in cancer biomarkers market with pharmaceutical companies ... in-demand companion diagnostic tests. ... --> Complete report on global cancer ...
(Date:11/26/2015)... 2015 ... Research Laboratories, a leading independent and ... has formed a strategic partnership with ... Health for joint work on clinical ... ) , --> ,     ...
Breaking Biology Technology:
(Date:11/17/2015)... , Nov. 17, 2015  Vigilant Solutions announces ... joined its Board of Directors. --> ... after recently retiring from the partnership at TPG Capital, ... companies with over $140 Billion in revenue.  He founded ... across all the TPG companies, from 1997 to 2013.  ...
(Date:11/12/2015)... CAMBRIDGE, Mass. , Nov. 12, 2015 /PRNewswire/ ... Broad Institute of MIT and Harvard for use ... chemical discovery information management tools. The partnership will ... share both biological and chemical research information internally ... tools will be used for managing the Institute,s ...
(Date:11/10/2015)... Nov. 10, 2015 About ... that helps to identify and verify the identity ... considered as the secure and accurate method of ... a particular individual because each individual,s signature is ... especially when dynamic signature of an individual is ...
Breaking Biology News(10 mins):